Long-term use survey of fostamatinib for ITP
Treatments studied
Part of Blood & lymphatic clinical trials.
This study follows people with chronic immune thrombocytopenia (ITP) who are starting fostamatinib for the first time. It aims to gather information on how well the medicine works and how safe it is when used over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic ITP (low platelets that have lasted for a while).
- You will be taking fostamatinib for the first time.
- You agree to take part in this survey and allow your health information to be collected.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the benefits and safety of continuing fostamatinib over the long term for people with warm autoimmune hemolytic anemia. It may help by reducing the body’s immune attack on red blood cells, and it’s designed for people who already finished a prior part of the study.
This study is a registry that collects medical information from adults who are newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or who are starting a treatment called fosfamatinib. It can help doctors understand these conditions better and improve future care.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hear when a new Chronic Idiopathic Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.